Enlivex Therapeutics Newsroom

Enlivex Therapeutics Ltd. Receives Approval for Phase I Trial of Allocetra in TMJ Osteoarthritis Patients

Quiver QuantitativeDec 11 08:43 ET

Express News | Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

BenzingaDec 11 08:32 ET

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis

GlobeNewswireDec 11 08:30 ET

Express News | D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

BenzingaDec 3 09:36 ET

Express News | Elivex Therapeutics Shares Are Trading Higher After the Company Announced Interim Efficacy Data Showing Statistical Significance and Marked Improvements for Its Allocetra Trial

BenzingaDec 3 09:14 ET

Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis

BenzingaDec 3 08:32 ET

Express News | Enlivex Therapeutics Ltd - Interim Results Show Statistically Significant Improvements in Pain and Functionality

ReutersDec 3 08:30 ET

Enlivex Therapeutics Faces Financial Challenges Amid Losses

TipRanksNov 29 16:58 ET

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

AccesswireNov 26 10:15 ET

MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 -- Barrons.com

Barron'sNov 22 12:25 ET

Express News | Enlivex Board Approves Purchase Of Up To $1M Of Bitcoin

BenzingaNov 20 08:01 ET

Enlivex Adopts Bitcoin Treasury Reserve Strategy

GlobeNewswireNov 20 08:00 ET

Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital

Dow JonesNov 14 17:12 ET · Ratings

Enlivex Therapeutics Price Target Maintained With a $13.00/Share by D. Boral Capital

Dow JonesNov 14 17:12 ET · Ratings

Enlivex Therapeutics Analyst Ratings

BenzingaNov 14 17:00 ET · Ratings

Express News | Enlivex Therapeutics Ltd - Psoriatic Arthritis Treatment Market Projected to Reach $20.5 Billion by 2032

ReutersNov 14 08:00 ET

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients With Psoriatic Arthritis

GlobeNewswireNov 14 08:00 ET

Express News | Enlivex Announces Enrollment And Dosing Of First 10 Patients In The Randomized Phase II Stage Of Its Allocetra Trial For Patients With Moderate To Severe Knee Osteoarthritis

BenzingaNov 12 08:06 ET

Enlivex Therapeutics Gets Japan Patent Notice for Allocetra in Osteoarthritis Treatment

MT NewswiresOct 30 11:09 ET

Express News | Enlivex Therapeutics Ltd - Patent Expected to Be Issued in Japan by Q2 2025

ReutersOct 30 08:03 ET